Testing effectiveness (Phase 2)UnknownNCT04248387What this trial is testingToripalimab in the Neoadjuvant Treatment of BRAF V600 Wild Type MelanomaWho this might be right forMelanoma Stage IIIB-IV Fudan University 100
Testing effectiveness (Phase 2)Study completedNCT02308553What this trial is testingEfficacy and Safety of Nintedanib Combined With Paclitaxel Chemotherapy for Patients With BRAF wt Metastatic MelanomaWho this might be right forCutaneous Malignant Melanoma Prof. Dr. med. Dirk Schadendorf 33
Testing effectiveness (Phase 2)Ended earlyNCT04375527What this trial is testingBinimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype MelanomaWho this might be right forClinical Stage III Cutaneous Melanoma AJCC V8Clinical Stage IV Cutaneous Melanoma AJCC V8Locally Advanced Cutaneous Melanoma+8 more Jonsson Comprehensive Cancer Center 3
Testing effectiveness (Phase 2)Active Not RecruitingNCT03175432What this trial is testingBevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain MetastasesWho this might be right forBRAF V600 Wild TypeClinical Stage IV Cutaneous Melanoma AJCC v8Intracranial Melanoma+4 more M.D. Anderson Cancer Center 29
Testing effectiveness (Phase 2)Study completedNCT04059224What this trial is testingTraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type MelanomaWho this might be right forStage IV MelanomaStage III Melanoma Universitair Ziekenhuis Brussel 45
Early research (Phase 1)Study completedNCT03178851What this trial is testingCobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced MelanomaWho this might be right forMalignant Melanoma Hoffmann-La Roche 155
Large-scale testing (Phase 3)Ended earlyNCT03273153What this trial is testingCobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type MelanomaWho this might be right forAdvanced BRAFV600 Wild-type Melanoma Hoffmann-La Roche 446